<article id="efficacy_wAMD_maintenance" class="slide efficacy-chart" data-ag-name="Efficacy wAMD Maintenance">
  <div class="tab-title">wAMD</div>
  <h2 class="slide-title">PRIMARY ENDPOINT: EYLEA<sup class="reg">&reg;</sup> DEMONSTRATED <br>VISION MAINTENANCE AT WEEK 52<sup class="footnote-link">1</sup></h2>
  <div class="chart">
    <div class="chart-desc">
      Proportion of patients maintaining vision at 1 year (<15 letters lost compared to baseline)
    </div>
  <div class="chart-img"><img src="content_EN/img/charts_vm-wamd.png" /></div>
    <div class="chart-details">
      <span>Adapted from EYLEA<sup class="reg">&reg;</sup> Product Monograph.</span> <span>Treatment Difference: VIEW 1 (0.7%; 95% CI [-3.1, 4.5]); VIEW 2 (1.1%, 95% CI [-2.6, 4.8])</span>
    </div>
    <div class="further-details two-lines">
       <p>EYLEA<sup class="reg">&reg;</sup> once every 2 months (after 3 initial monthly doses) demonstrated comparable vision maintenance vs. monthly ranibizumab</p>
               <span class="parallelogram"></span>
    </div>
  </div>
  <div class="reveal-study-design"><span>+</span><span>Study Design</span></div>
  <div id="popup-text">
    <h3>STUDY DESIGN</h3>
    <p>
      <span class='bullet'>*</span>VIEW 1 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=303), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=304), EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=304) or ranibizumab 0.5&nbsp;mg Q4 (n=306). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50 µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months.
    </p>
    <p>
      <span class='bullet'>†</span>VIEW 2 was a randomized, multicentre, double-blind, active-controlled study in adult patients with wAMD. Patients were assigned in a 1:1:1:1 ratio to either EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q8 following 3 initial monthly doses (n=313), EYLEA<sup class="reg">&reg;</sup> 2&nbsp;mg Q4 (n=313), EYLEA<sup class="reg">&reg;</sup> 0.5&nbsp;mg Q4 (n=311) or ranibizumab 0.5&nbsp;mg Q4 (n=303). This trial included doses that differ from the recommended dose of EYLEA<sup class="reg">&reg;</sup>. The recommended dose of EYLEA<sup class="reg">&reg;</sup> is 2&nbsp;mg (0.05&nbsp;mL, or 50 µL) administered by intravitreal injection monthly for 3 initial doses followed by one dose administered once every 2 months.
    </p>
  </div>
</article>